The HER-2-positive CRC patients exhibited higher three- and five-year survival rates compared with HER-2-negative patients (77.7 vs. 68.8% and 77.7 vs. 61.4%, respectively); however, the difference was not statistically significant (P=0.082; Fig. 3). This evidence concerns the gene ERBB2 and colorectal carcinoma.